Titlebook: Current Controversies in Bone Marrow Transplantation; Brian J. Bolwell (Director, Staff Physician) Book 2000 Humana Press Inc. 2000 blood.

饒舌的人

Scintillations

藐視

Petter Gottschalk,Christopher Hamertoneripheral blood progenitor cell transplantation (PBPCT) over the past two decades. The use of ABMT in non-Hodgkin’s lymphoma (NHL) is an unequivocal success. AMBT now represents state-of-the-art care for many lymphoma patients, and has changed the standard of care for such patients worldwide. In the

宮殿般

時(shí)代錯(cuò)誤

,Conclusion: Why It Didn’t Happen Here,cades. Despite expanding knowledge of genetics, prognostic factors, and biology, as well as advances in surgical management, adjuvant chemotherapy (CT), and radiotherapy, many women will die from progressive, metastatic breast cancer (MBC). Over the past 10 yr, many investigators have studied the ro

Obsequious

arbiter

Worldviews, Ethics and Organizational Lifey curable, particularly when discovered early, stage at presentation is the predominant factor in determining outcome and treatment. Fortunately, even patients who present with disseminated disease can be cured with cisplatin-based combination chemotherapy (CT) and aggressive surgical extirpation of

酷熱

adroit

施魔法

Is Autologous Transplantation for Non-Hodgkin’s Lymphoma Underutilized?ntional-dose CT, and cure some patients who are otherwise incurable. With current techniques utilizing hematopoietic growth factors and PBPCs, mortality risks have decreased to 1–3%. The well-documented efficacy, coupled with decreased morbidity and mortality, have led to clinical research studies u